Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

  • Jan J. Cornelissen
  • Alois Gratwohl
  • Richard F. Schlenk
  • Jorge Sierra
  • Martin Bornhaeuser
  • Gunnar Juliusson
  • Zdenek Racil
  • Jacob M. Rowe
  • Nigel Russell
  • Mohamad Mohty
  • Bob Lowenberg
  • Gerard Socie
  • Dietger Niederwieser
  • Gert J. Ossenkoppele
Publiceringsår: 2012
Språk: Engelska
Sidor: 579-590
Publikation/Tidskrift/Serie: Nature Reviews Clinical Oncology
Volym: 9
Nummer: 10
Dokumenttyp: Artikel i tidskrift
Förlag: Nature Publishing Group


Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach.


  • Cancer and Oncology


  • ISSN: 1759-4782

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen